CN112915136A - Pharmaceutical composition with anti-inflammatory and immune effects, and preparation method and application thereof - Google Patents
Pharmaceutical composition with anti-inflammatory and immune effects, and preparation method and application thereof Download PDFInfo
- Publication number
- CN112915136A CN112915136A CN202110368961.8A CN202110368961A CN112915136A CN 112915136 A CN112915136 A CN 112915136A CN 202110368961 A CN202110368961 A CN 202110368961A CN 112915136 A CN112915136 A CN 112915136A
- Authority
- CN
- China
- Prior art keywords
- parts
- mixed
- solid
- inflammatory
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention discloses a pharmaceutical composition with anti-inflammatory and immune effects, a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The solid beverage is prepared by using eucommia ulmoides leaves, acanthopanax senticosus, astragalus mongholicus, liquorice and tea as raw materials, the effect of the solid beverage can be improved by adding the compound extract mainly comprising the astragalus mongholicus, the liquorice and the tea, the taste of the beverage is adjusted, the unpleasant feeling caused by the herbal extract is reduced, the 'zero-sugar addition' is realized, and the solid beverage is friendly to patients with chronic diseases such as diabetes, hypertension and the like.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition with anti-inflammatory and immune effects, a preparation method and application thereof.
Background
Acanthopanax senticosus has anti-inflammatory and immunity enhancing effects, and can prevent fatigue, promote recovery, provide energy for muscle activity in time, promote synthesis of protein and nucleic acid, and enhance mental and physical activities. Folium Eucommiae has effects of lowering blood pressure, preventing osteoporosis, lowering blood sugar, regulating blood lipid, regulating immunity, relieving fatigue and resisting oxidation.
There are many reports about the composition formed by acanthopanax and eucommia leaves, and most of the product patents are flavoured by sweetener or sugar substitute, such as CN201811597472.4, CN200510042876.3, and the like, which are not beneficial for consumers to eat for a long time.
In view of this, the invention is particularly proposed.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition with anti-inflammatory and immune effects and a preparation method thereof, and aims to avoid the use of a sweetener or sugar substitute and prepare a product which has good anti-inflammatory and immune effects and is suitable for long-term consumption.
The invention also aims to provide the application of the pharmaceutical composition in preparing medicaments with anti-inflammatory and immune effects.
The invention is realized by the following steps:
the invention provides a pharmaceutical composition with anti-inflammatory and immune effects, which comprises the following raw materials in parts by weight: 10-100 parts of eucommia leaf, 10-100 parts of acanthopanax, 10-100 parts of astragalus, 1-100 parts of liquorice and 10-5000 parts of tea.
The invention also provides a preparation method of the medicine with the anti-inflammatory and immune effects, which adopts the raw materials for preparation.
The invention also provides application of the pharmaceutical composition in preparing a medicament with anti-inflammatory and immune effects.
The invention has the following beneficial effects: the invention is prepared by taking eucommia ulmoides leaves, acanthopanax senticosus, astragalus membranaceus, liquorice and tea as raw materials, and the astragalus membranaceus, the liquorice and the tea are used for synergism and seasoning, so that the taste and taste acceptance is improved, and the influence of using a sweetener or sugar substitute on the long-term use of the product is avoided.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The embodiment of the invention provides a pharmaceutical composition with anti-inflammatory and immune effects, which comprises the following raw materials in parts by weight: 10-100 parts of eucommia leaf, 10-100 parts of acanthopanax, 10-100 parts of astragalus, 1-100 parts of liquorice and 10-5000 parts of tea.
The inventor creatively uses eucommia leaves, acanthopanax, radix astragali, liquorice and tea leaves as raw materials for preparation, uses the radix astragali, the liquorice and the tea leaves for synergism and seasoning, improves the acceptance of taste and sense of taste, and avoids using a sweetener or sugar substitute to influence the long-term use of the product.
In order to further improve the efficacy of the eucommia ulmoides leaves and the acanthopanax senticosus, the inventor further adjusts the dosage of each component. The raw materials comprise the following components in parts by weight: 10-90 parts of eucommia leaf, 10-50 parts of acanthopanax, 10-90 parts of astragalus, 10-90 parts of liquorice and 10-100 parts of tea; preferably, the raw materials comprise: 20-80 parts of eucommia leaf, 20-40 parts of acanthopanax, 10-30 parts of astragalus, 10-30 parts of liquorice and 20-100 parts of tea; more preferably, the raw materials thereof comprise: 20 parts of eucommia leaves, 30 parts of acanthopanax, 5 parts of astragalus, 5 parts of liquorice and 100 parts of tea leaves.
The anti-inflammatory and immune effects can be further improved by further controlling the dosage of the eucommia ulmoides leaves, the acanthopanax senticosus, the astragalus mongholicus, the liquorice and the tea leaves. The inventors have determined precisely the preferred amounts of the components by directly determining the protective effect of the product on inflammatory cells induced by LPS and the effect on inflammatory cells (NO, TNF-alpha, IL-1 beta, IL-6). Compared with the traditional evaluation standard taking the components as the advantages and disadvantages of the effects, the evaluation method in the embodiment of the invention is more objective and accurate.
The embodiment of the invention also provides a preparation method of the medicine with the anti-inflammatory and immune effects, which adopts the raw materials for preparation, and prepares a product with good anti-inflammatory and immune effects, good taste and no sweetener or sugar substitute by regulating and controlling the dosage of each component.
In a preferred embodiment, the preparation method comprises the following steps: mixing folium Eucommiae and radix Acanthopanacis Senticosi, extracting to obtain mixed extractive solution, concentrating, drying to solid, and mixing the dried solid with solid extracts of radix astragali, radix Glycyrrhizae and folium Camelliae sinensis. The solid effective component is prepared by concentrating and drying the extract, and then mixing with mixed extracts of radix astragali, Glycyrrhrizae radix and folium Camelliae sinensis, wherein radix astragali, Glycyrrhrizae radix and folium Camelliae sinensis are added in the form of compound concentrated extract, and can be made into solid beverage.
In some embodiments, the mixed extraction method of the eucommia ulmoides leaves and the acanthopanax senticosus is heating reflux extraction, and the specific operation method can adopt the existing water extraction process, which is not limited herein.
Preferably, the process of heating reflux extraction comprises: mixing folium Eucommiae and radix Acanthopanacis Senticosi with water, extracting for at least 2 times, and mixing extractive solutions; the temperature of each extraction is 60-80 deg.C, such as 60 deg.C, 70 deg.C, 80 deg.C, or any value between two adjacent temperature values.
Specifically, the process of heating reflux extraction comprises the following steps: mixing folium Eucommiae and radix Acanthopanacis Senticosi with water, extracting for 0.8-1.2 hr (such as 0.8 hr, 0.9 hr, 1.0 hr, 1.1 hr, 1.2 hr, etc.), separating solid and liquid to obtain filter residue and first extractive solution, mixing the filter residue with water, extracting for 0.3-0.8 hr, mixing the two extractive solutions, and performing solid and liquid separation for the second time; the amount of water used in the primary extraction process is 8-12 times of the mass of the mixed materials, and the amount of water used in the secondary extraction process is 6-10 times of the mass of the filter residue.
It should be noted that the inventor is favorable to further improve the extraction effect and extract the effective components in the eucommia ulmoides leaves and the acanthopanax senticosus to a greater extent by further regulating and controlling the specific process and parameters in the heating reflux extraction process.
In another embodiment, the mixed extraction of folium Eucommiae and radix Acanthopanacis Senticosi is performed by wet ultrafine pulverization, and the inventors found that the wet ultrafine pulverization is beneficial for improving the drug effect of the extractive solution, probably because the wet ultrafine pulverization can better destroy cells and release them.
Further, the wet ultrafine grinding extraction process comprises the following steps: premixing folium Eucommiae, radix Acanthopanacis Senticosi and water, pulverizing in wet superfine pulverizing equipment until the center particle size of the mixed raw materials reaches below 10 μm, and performing solid-liquid separation. Wherein the amount of water in the premix is 5-15 times of the total mass of folium Eucommiae and radix Acanthopanacis Senticosi, such as 5 times, 8 times, 10 times, 12 times, 15 times, etc.
Specifically, the crushing time in the wet superfine crushing equipment is 5-90 min; preferably 8-12min, such as 8min, 9min, 10min, 11min, 12min, etc. The drug effect of the extracting solution can be further ensured and the anti-inflammatory immunity effect can be enhanced by further regulating and controlling the crushing time in the wet superfine crushing equipment, if the crushing time is too short, the effective components cannot be fully extracted, and if the crushing time is too long, the degradation of the effective components can be caused to influence the drug effect.
In some embodiments, the mixed extract is concentrated to a solid content of 20-50% for subsequent preparation by drying to obtain the solid active ingredient.
In a preferred embodiment, the mixed extract is filtered by microfiltration to obtain a clear liquid before concentrating the mixed extract, so as to further remove small-particle filter residues. Specifically, microfiltration membrane filtration is an existing filtration mode, the specific pore size of the microfiltration membrane is not limited, and a common commercially available microfiltration membrane can be adopted.
The compound concentrated extract can be obtained by extracting astragalus, liquorice and tea leaves serving as raw materials in a conventional manner, filtering with a microfiltration membrane, concentrating and drying, wherein the extraction manner can be common water extraction. The addition of the compound extract mainly comprising astragalus, liquorice and tea can improve the efficacy of the solid beverage, adjust the mouthfeel of the beverage, reduce the unpleasant feeling brought by the herbal extract, realize 'zero sugar addition', and is friendly to patients with chronic diseases such as diabetes, hypertension and the like.
Specifically, the tea leaves include general tea leaf extracts such as green tea, black tea and the like.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
The embodiment provides a preparation method of a medicine with anti-inflammatory and immune effects, which comprises the following steps:
(1) 40g of acanthopanax and 15g of folium cortex eucommiae are accurately weighed, namely the mass ratio of the acanthopanax to the folium cortex eucommiae is controlled to be 8: 3.
(2) Adding 10 times of pure water into the mixture obtained in the step (1), and heating the mixture to 70 ℃ for extraction for 1 hour. And after solid-liquid separation, adding 8 times of pure water into the filter residue, extracting for 0.5 hour, and combining the extracting solutions to carry out preliminary solid-liquid separation to obtain the extracting solution.
(3) And (3) filtering the extracting solution in the step (2) by using a microfiltration membrane until the extracting solution is clear.
(4) And (4) concentrating the extracting solution in the step (3) until the solid content is 20%, and drying to obtain a solid.
(5) Adding 1:1, the compound concentrated extract is prepared by mixing astragalus, liquorice and green tea according to the mass ratio of 1:1:10, extracting with water, filtering with a microfiltration membrane, concentrating and drying.
Example 2
The embodiment provides a preparation method of a medicine with anti-inflammatory and immune effects, which comprises the following steps:
(1) accurately weighing 20g of acanthopanax and 30g of folium cortex eucommiae, namely controlling the mass ratio of the acanthopanax and the folium cortex eucommiae to be 2: 3.
(2) Adding 10 times of pure water into the mixture obtained in the step (1), and heating the mixture to 70 ℃ for extraction for 1 hour. And after solid-liquid separation, adding 8 times of pure water into the filter residue, extracting for 0.5 hour, and combining the extracting solutions to carry out preliminary solid-liquid separation to obtain the extracting solution.
(3) And (3) filtering the extracting solution in the step (2) by using a microfiltration membrane until the extracting solution is clear.
(4) And (4) concentrating the extracting solution in the step (3) until the solid content is 30%, and drying to obtain a solid.
(5) Adding 1:1, the compound concentrated extract is prepared by mixing astragalus, liquorice and dark green tea according to the mass ratio of 1:1:20, extracting with water, filtering with a microfiltration membrane, concentrating and drying.
Example 3
The embodiment provides a preparation method of a medicine with anti-inflammatory and immune effects, which comprises the following steps:
(1) accurately weighing 20g of acanthopanax and 30g of folium cortex eucommiae, namely controlling the mass ratio of the acanthopanax and the folium cortex eucommiae to be 2: 3.
(2) Adding 10 times of pure water into the mixed raw materials in the step (1), and premixing the mixed raw materials and the water. And (3) continuously crushing for 5 minutes in a water environment under a wet superfine crushing device, finally, after the central granularity of the acanthopanax root-eucommia bark leaf mixed raw material is less than 10 mu m, finishing extraction, and carrying out primary solid-liquid separation on the extracting solution by using gauze to obtain the extracting solution.
(3) And (3) filtering the extracting solution in the step (2) by using a microfiltration membrane until the extracting solution is clear.
(4) And (4) concentrating the extracting solution in the step (3) until the solid content is 30%, and drying to obtain a solid.
(5) Adding 1:1, the compound concentrated extract is prepared by mixing astragalus, liquorice and black tea according to the mass ratio of 1:1:10, extracting with water, filtering with a microfiltration membrane, concentrating and drying.
Example 4
The embodiment provides a preparation method of a medicine with anti-inflammatory and immune effects, which comprises the following steps:
(1) accurately weighing 20g of acanthopanax and 30g of folium cortex eucommiae, namely controlling the mass ratio of the acanthopanax and the folium cortex eucommiae to be 2: 3.
(2) Adding 10 times of pure water into the mixed raw materials in the step (1), and premixing the mixed raw materials and the water. And (3) continuously crushing for 10 minutes in a water environment under a wet superfine crushing device, finally, after the central granularity of the acanthopanax root-eucommia bark leaf mixed raw material is less than 10 mu m, finishing extraction, and carrying out primary solid-liquid separation on the extracting solution by using gauze to obtain the extracting solution.
(3) And (3) filtering the extracting solution in the step (2) by using a microfiltration membrane until the extracting solution is clear.
(4) And (4) concentrating the extracting solution in the step (3) until the solid content is 40%, and drying to obtain a solid.
(5) Adding 1:1, the compound concentrated extract is prepared by mixing astragalus, liquorice and green tea according to the mass ratio of 1:1:50, extracting with water, filtering with a microfiltration membrane, concentrating and drying.
Example 5
The embodiment provides a preparation method of a medicine with anti-inflammatory and immune effects, which comprises the following steps:
(1) 10g of acanthopanax senticosus and 10g of eucommia ulmoides leaves are accurately weighed.
(2) Adding 10 times of pure water into the mixed raw materials in the step (1), and premixing the mixed raw materials and the water. And (3) continuously crushing for 8 minutes in a water environment under a wet superfine crushing device, finally, after the central granularity of the acanthopanax root-eucommia bark leaf mixed raw material is less than 10 mu m, finishing extraction, and carrying out primary solid-liquid separation on the extracting solution by using gauze to obtain the extracting solution.
(3) And (3) filtering the extracting solution in the step (2) by using a microfiltration membrane until the extracting solution is clear.
(4) And (4) concentrating the extracting solution in the step (3) until the solid content is 20%, and drying to obtain a solid.
(5) And (3) adding a compound concentrated extract into the solid in the step (4), wherein the compound concentrated extract is prepared by mixing 10g of astragalus, 1g of liquorice and 10g of green tea, carrying out water extraction, filtering by using a microfiltration membrane, concentrating and drying.
Example 6
The embodiment provides a preparation method of a medicine with anti-inflammatory and immune effects, which comprises the following steps:
(1) 100g of acanthopanax and 100g of eucommia ulmoides leaves are accurately weighed.
(2) Adding 10 times of pure water into the mixed raw materials in the step (1), and premixing the mixed raw materials and the water. And (3) continuously crushing for 12 minutes in a water environment under a wet superfine crushing device, finally, after the central granularity of the acanthopanax root-eucommia bark leaf mixed raw material is less than 10 mu m, finishing extraction, and carrying out primary solid-liquid separation on the extracting solution by using gauze to obtain the extracting solution.
(3) And (3) filtering the extracting solution in the step (2) by using a microfiltration membrane until the extracting solution is clear.
(4) And (4) concentrating the extracting solution in the step (3) until the solid content is 50%, and drying to obtain a solid.
(5) And (4) adding a compound concentrated extract into the solid in the step (4), wherein the compound concentrated extract is prepared by mixing 100g of astragalus mongholicus, 100g of liquorice and 5000g of dark green tea, carrying out water extraction, filtering by using a microfiltration membrane, concentrating and drying.
Test examples
The solid extracts obtained in step (4) of examples 1 to 4 were tested for efficacy by the following test methods: two experiments were performed with the solid in (4) formulated as a 100. mu.g/ml liquid, for protection of inflammatory cells induced by LPS and for effects on inflammatory cells (NO, TNF-. alpha., IL-1. beta., IL-6). The test method is a conventional test method and can refer to the analysis of the expression profile change of the circular RNA in the mouse abdominal cavity macrophage inflammatory reaction induced by the LPS.
The results show that:
solid extract in example 1: (1) the protective effect of LPS induced inflammatory cells is 58.2% (55.86% of LPS induced inflammation control group), and the protective effect on the LPS induced inflammatory cells is obvious (p is less than 0.01 or p is less than 0.001); (2) effect on inflammatory cells NO: 28.63 mu mol/L (37.16 mu mol/L in an LPS-induced inflammation control group), the NO content can be obviously reduced; TNF- α: 408.5pg/mL (373.5 pg/mL in the control group of inflammation induced by LPS), with no significant change; IL-1. beta.: 31.77pg/mL (37.87 pg/mL in an LPS-induced inflammation control group), the content of IL-1 beta can be obviously reduced; IL-6: 34.30pg/mL (40.55 pg/mL in control group of inflammation induced by LPS), the IL-6 content can be obviously reduced.
Solid extract in example 2: (1) the protective effect of LPS induced inflammatory cells is 68.2% (55.86% of LPS induced inflammation control group), and the protective effect on the LPS induced inflammatory cells is obvious (p is less than 0.01 or p is less than 0.001); (2) effect on inflammatory cells NO: 27.71 mu mol/L (37.16 mu mol/L of an LPS-induced inflammation control group), the NO content can be obviously reduced; TNF- α: 323.5pg/mL (373.5 pg/mL in the control group of inflammation induced by LPS) can significantly reduce the content of TNF-alpha; IL-1. beta.: 28.41pg/mL (37.87 pg/mL in the control group of inflammation induced by LPS) can obviously reduce the content of IL-1 beta; IL-6: 23.36pg/mL (40.55 pg/mL in control group of inflammation induced by LPS) can significantly reduce IL-6 content.
Solid extract in example 3: (1) the protective effect of LPS induced inflammatory cells is 52.86% (42.86% of LPS induced inflammation control group), and the protective effect on the LPS induced inflammatory cells is obvious (p is less than 0.01 or p is less than 0.001); (2) effect on inflammatory cells NO: 25.73 mu mol/L (52.07 mu mol/L of an LPS-induced inflammation control group), the NO content can be obviously reduced; TNF- α: 266.36pg/mL (328.18 pg/mL in the control group of inflammation induced by LPS) can significantly reduce the content of TNF-alpha; IL-1. beta.: 63.96pg/mL (88.58 pg/mL in control group of inflammation induced by LPS) can obviously reduce IL-1 beta content; IL-6: 91.05pg/mL (125.26 pg/mL controlled by LPS-induced inflammation) significantly reduced IL-6 levels.
Solid extract in example 4: (1) the protective effect of LPS induced inflammatory cells is 80.00% (42.86% of LPS induced inflammation control group), and the protective effect on the LPS induced inflammatory cells is obvious (p is less than 0.01 or p is less than 0.001); (2) effect on inflammatory cells NO: 34.62 mu mol/L (52.07 mu mol/L after LPS induces inflammation control group), the NO content can be obviously reduced; TNF- α: 350.9pg/mL (328.18 pg/mL controlled inflammation induced by LPS) with no significant TNF-alpha content change; IL-1. beta.: 87.09pg/mL (88.58 pg/mL in the control group of LPS-induced inflammation) without significantly reducing IL-1. beta. content; IL-6: 117.37pg/mL (125.26 pg/mL controlled by LPS-induced inflammation) significantly reduced IL-6 levels.
The test results of comparative example 1 and example 2 show that: the mass ratio of the acanthopanax and the eucommia leaves is controlled to be 2: 3; comparative example 2 and comparative examples 3 to 4 show that: the wet superfine grinding and extraction method is adopted, and the grinding time is controlled to be 10min as the optimal condition.
In summary, the pharmaceutical composition with anti-inflammatory and immune effects, the preparation method and the application thereof provided by the embodiment of the invention are prepared by using folium cortex eucommiae, acanthopanax senticosus, radix astragali, liquorice and tea as raw materials, and the addition of the composite extract mainly containing radix astragali, liquorice and tea can increase the efficacy of the solid beverage, adjust the taste of the beverage, reduce the unpleasant feeling caused by the herbal extract, realize 'zero sugar addition', and be friendly to patients with chronic diseases such as diabetes, hypertension and the like.
The above is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and various modifications and changes will occur to those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The pharmaceutical composition with the anti-inflammatory and immune effects is characterized by comprising the following components in parts by weight: 10-100 parts of eucommia leaf, 10-100 parts of acanthopanax, 10-100 parts of astragalus, 1-100 parts of liquorice and 10-5000 parts of tea.
2. The pharmaceutical composition with anti-inflammatory and immune effects as claimed in claim 1, wherein the raw materials comprise, in parts by weight: 10-90 parts of eucommia leaf, 10-50 parts of acanthopanax, 10-90 parts of astragalus, 10-90 parts of liquorice and 10-100 parts of tea;
preferably, the raw materials comprise: 20-80 parts of eucommia leaf, 20-40 parts of acanthopanax, 10-30 parts of astragalus, 10-30 parts of liquorice and 20-100 parts of tea;
more preferably, the raw materials thereof comprise: 20 parts of eucommia leaves, 30 parts of acanthopanax, 5 parts of astragalus, 5 parts of liquorice and 100 parts of tea leaves.
3. A method for preparing a drug with anti-inflammatory and immune effects, which is prepared by using the raw material as described in claim 1 or 2.
4. The method of claim 3, comprising: mixing folium Eucommiae and radix Acanthopanacis Senticosi, extracting to obtain mixed extractive solution, concentrating and drying the mixed extractive solution to solid, and mixing the dried solid with solid extracts of radix astragali, radix Glycyrrhizae and folium Camelliae sinensis.
5. The method according to claim 4, wherein the mixed extraction of folium Eucommiae and radix Acanthopanacis Senticosi is performed by heating and refluxing;
preferably, the process of heating reflux extraction comprises: mixing folium Eucommiae and radix Acanthopanacis Senticosi with water, extracting for at least 2 times, and mixing extractive solutions;
preferably, the temperature of each extraction is 60-80 ℃.
6. The method of claim 5, wherein the heating reflux extraction process comprises: mixing folium Eucommiae and radix Acanthopanacis Senticosi with water, extracting for 0.8-1.2 hr, performing solid-liquid separation to obtain filter residue and first extractive solution, mixing the filter residue with water, extracting for 0.3-0.8 hr, mixing the two extractive solutions, and performing solid-liquid separation for the second time;
preferably, the amount of water used in the primary extraction process is 8-12 times of the mass of the mixed material, and the amount of water used in the secondary extraction process is 6-10 times of the mass of the filter residue.
7. The method of claim 4, wherein the mixed extraction of folium Eucommiae and radix Acanthopanacis Senticosi is performed by wet ultrafine pulverization;
preferably, the wet ultrafine grinding extraction process comprises the following steps: premixing folium Eucommiae, radix Acanthopanacis Senticosi and water, pulverizing in wet superfine pulverizing equipment until the central particle size of the mixed raw materials reaches below 10 μm, and performing solid-liquid separation;
preferably, the crushing time in the wet superfine crushing equipment is 5-90 min; more preferably 5-20 min.
8. The preparation method according to claim 7, wherein the amount of the water used in the pre-mixing is 5 to 15 times of the total mass of the eucommia ulmoides leaves and the acanthopanax senticosus.
9. The method according to claim 4, wherein the mixed extract is filtered by microfiltration before the mixed extract is concentrated;
preferably, the process of concentrating the mixed extracting solution is to concentrate the mixed extracting solution until the solid content is 20-50%.
10. Use of a pharmaceutical composition according to claim 1 or 2 for the manufacture of a medicament with anti-inflammatory immune efficacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110368961.8A CN112915136A (en) | 2021-04-06 | 2021-04-06 | Pharmaceutical composition with anti-inflammatory and immune effects, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110368961.8A CN112915136A (en) | 2021-04-06 | 2021-04-06 | Pharmaceutical composition with anti-inflammatory and immune effects, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112915136A true CN112915136A (en) | 2021-06-08 |
Family
ID=76174276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110368961.8A Pending CN112915136A (en) | 2021-04-06 | 2021-04-06 | Pharmaceutical composition with anti-inflammatory and immune effects, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112915136A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078099A (en) * | 1992-04-30 | 1993-11-10 | 薛和平 | The manufacture method of a kind of health tea |
| CN101385772A (en) * | 2008-01-09 | 2009-03-18 | 姜宝库 | Effervescence tablets for increasing natural immunity |
| CN101731387A (en) * | 2010-01-11 | 2010-06-16 | 邵伟 | Siberian ginseng and eucommia bark leaf black tea |
| CN102669333A (en) * | 2012-06-08 | 2012-09-19 | 贵州铜仁和泰茶业有限公司 | Eucommia ulmoides oliv tea bag and producing method thereof |
-
2021
- 2021-04-06 CN CN202110368961.8A patent/CN112915136A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078099A (en) * | 1992-04-30 | 1993-11-10 | 薛和平 | The manufacture method of a kind of health tea |
| CN101385772A (en) * | 2008-01-09 | 2009-03-18 | 姜宝库 | Effervescence tablets for increasing natural immunity |
| CN101731387A (en) * | 2010-01-11 | 2010-06-16 | 邵伟 | Siberian ginseng and eucommia bark leaf black tea |
| CN102669333A (en) * | 2012-06-08 | 2012-09-19 | 贵州铜仁和泰茶业有限公司 | Eucommia ulmoides oliv tea bag and producing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王沛: "《制药原理与设备》", 31 January 2019, 上海科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105767397A (en) | Spleen-invigorating and stomach-harmonizing gingko tea | |
| CN108261434A (en) | Sanchi flower, stem-leaf extract, the instant tea containing sanchi flower, stem-leaf extract, and preparation method thereof | |
| CN108310040A (en) | A kind of multi-functional medicine materical crude slice | |
| CN107950929A (en) | It is a kind of that there is composition for improving sleep function and its preparation method and application | |
| CN104474472B (en) | Buccal lozenge of lectuce tea and its production method with three high drop effect | |
| CN1833686A (en) | Pure Chinese medicinal hypotensor | |
| CN108126026A (en) | The preparation method of cordyceps sinensis QISHEN CAPSULE | |
| CN108721379A (en) | A kind of summer Sang Ju Yin pharmaceutical preparation and its preparation method and application | |
| CN105076600A (en) | Weight-reducing herbal tea beverage and preparation method thereof | |
| CN112915136A (en) | Pharmaceutical composition with anti-inflammatory and immune effects, and preparation method and application thereof | |
| CN103999986A (en) | Herbal tea concentrated juice and preparation method thereof | |
| CN102552527A (en) | Traditional Chinese medicine composition used for treating diabetic complications and reducing blood sugar | |
| CN101244208A (en) | Method of preparing traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN103404811A (en) | Instant arrowroot and preparation technology thereof | |
| CN1288168C (en) | Polysaccharides compound preparation and method for preparing the same | |
| CN102613347A (en) | Gingko black tea and preparation method thereof | |
| CN1830281A (en) | Kuding tea | |
| CN102716255A (en) | Eucommia ulmoides medicinal wine and preparation method thereof | |
| CN110193034A (en) | A kind of eucommia leaf extract and its application in alleviation physical fatigue product | |
| CN101473940A (en) | Functional health-care food for depression and preparation method thereof | |
| CN108079219A (en) | A kind of topical composition for treating burn and scald and preparation method thereof | |
| CN107372967A (en) | A kind of tea-drinking for improving blood stasis constitution | |
| CN106578262A (en) | Bag eucommia tea granules and preparation method thereof | |
| CN102580042A (en) | Traditional Chinese medicine composition for treating wind-cold type of common cold and preparation method of traditional Chinese medicine composition | |
| CN100488543C (en) | Local externally applied itch stopping garlic liniments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210608 |
|
| RJ01 | Rejection of invention patent application after publication |